VaxInnate Raising $30 Million

VaxInnate Corp., a Cranbury, N.J.-based developer of vaccines for both pandemic and seasonal influenza, is almost done raising $30 million in new Series C funding, according to VentureWire. The company held an initial $40 million close on the round back in 2006, led by New Leaf Venture Partners. Other backers include Canaan Partners and return backers HealthCare Ventures, Oxford Bioscience Partners, MedImmune Ventures and CHL Medical Ventures.